In the past week, RAPP stock has gone up by 23.87%, with a monthly gain of 10.66% and a quarterly surge of 47.32%. The volatility ratio for the week is 8.79%, and the volatility levels for the last 30 days are 9.07% for Rapport Therapeutics Inc The simple moving average for the past 20 days is 19.18% for RAPP’s stock, with a -9.45% simple moving average for the past 200 days.
Is It Worth Investing in Rapport Therapeutics Inc (NASDAQ: RAPP) Right Now?
The 36-month beta value for RAPP is also noteworthy at 0.36. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for RAPP is 17.41M, and at present, short sellers hold a 16.27% of that float. The average trading volume of RAPP on July 10, 2025 was 169.60K shares.
RAPP) stock’s latest price update
Rapport Therapeutics Inc (NASDAQ: RAPP) has experienced a rise in its stock price by 11.01% compared to its previous closing price of $12.62. However, the company has seen a gain of 23.87% in its stock price over the last five trading days. marketbeat.com reported 2025-06-12 that The biopharmaceuticals industry is both exciting and risky for investors. Many leading growth stocks in the U.S. market are found in this sector, due to the significant rallies that biopharmaceutical companies experience when a key positive trial result is announced or an important drug receives government approval.
Analysts’ Opinion of RAPP
Stifel gave a rating of “Buy” to RAPP, setting the target price at $35 in the report published on July 02nd of the previous year.
RAPP Trading at 26.17% from the 50-Day Moving Average
After a stumble in the market that brought RAPP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -52.89% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RAPP starting from Bredt David, who sale 8,500 shares at the price of $11.00 back on Jun 16 ’25. After this action, Bredt David now owns 443,642 shares of Rapport Therapeutics Inc, valued at $93,522 using the latest closing price.
Stock Fundamentals for RAPP
The total capital return value is set at -0.32. Equity return is now at value -33.14, with -31.36 for asset returns.
Based on Rapport Therapeutics Inc (RAPP), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -8.6.
Currently, EBITDA for the company is -77.47 million with net debt to EBITDA at 0.54. The liquidity ratio also appears to be rather interesting for investors as it stands at 31.01.
Conclusion
In summary, Rapport Therapeutics Inc (RAPP) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
